share_log

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

2022年9月14日的重要生物技術催化劑-當天結束摘要
Benzinga Real-time News ·  2022/09/14 17:32
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON's (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares traded as high as 5.26 percent, in a range of $1.9 to $2 on day volume of 111.77 thousand shares, closed regular trading session at $1.9.
美國食品和藥物管理局(FDA)已批准快車道指定用於開發TRACON納斯達克(TCon)的主導資產envafolimab(KN035)適用於局部晚期、無法切除或轉移性未分化的多形性肉瘤(UPS)和粘液纖維肉瘤(MFS)患者,這些患者在既往的一到兩個化療方案中取得了進展。TRACON的股票交易價格高達5.26%,當日成交量為111.77萬股,在1.9美元到2美元的範圍內,常規交易時段收盤報1.9美元。
Centessa Pharmaceuticals (NASDAQ:CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B...
Centessa製藥公司納斯達克(Sequoia Ca...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論